MK 8291

Drug Profile

MK 8291

Latest Information Update: 22 Mar 2016

Price : $50

At a glance

  • Originator Merck Sharp & Dohme
  • Class Analgesics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Postherpetic neuralgia

Most Recent Events

  • 01 Feb 2016 Merck Sharp & Dohme completes a phase I trial for Postherpetic neuralgia in Bulgaria, Georgia, Moldova and Romania (NCT02336555)
  • 01 Mar 2015 Phase-I clinical trials in Postherpetic neuralgia in Georgia, Bulgaria (PO) (NCT02336555)
  • 12 Jan 2015 Preclinical trials in Postherpetic neuralgia in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top